LAVAL, QC, Feb. 11 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announces today that on Wednesday, February 13, 2008, Dr. Francesco Bellini,
Neurochem's Chairman, President and Chief Executive Officer, and Mr. Gary
Schmid, Chief Executive Officer of the new nutraceutical business, will
present Neurochem's strategy at the 2008 BIO CEO & Investor Conference to be
held at the Waldorf-Astoria, in New York (NY). The presentation will take
place at 11:00 A.M. EST, in the West Foyer room.
The live Web cast of Neurochem's presentation (audio and visual) can be
A replay of the presentation will begin one (1) hour after the actual
presentation time, and will be available until February 20, 2008. Please
access the Web cast approximately 15 minutes before the presentation is
scheduled to begin.
Neurochem Inc. is a global health company focused on the research,
development and commercialization of products to provide innovative health
solutions to address critical unmet medical needs.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical and/or
nutraceutical industry, changes in the regulatory environment in the
jurisdictions in which the Neurochem group does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, that actual results may vary once the final and
quality-controlled verification of data and analyses has been completed, as
well as other risks disclosed in public filings of Neurochem Inc.
Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. The reader should not
place undue reliance, if any, on any forward-looking statements included in
this news release. These statements speak only as of the date made and
Neurochem Inc. is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise,
unless required by applicable legislation or regulation. Please see the Annual
Information Form of Neurochem Inc. for further risk factors that might affect
the Neurochem group and its business.
For further information:
For further information: Lise Hébert, PhD, Vice President, Corporate
Communications, (450) 680-4572, firstname.lastname@example.org